GLP‑1 Receptor Agonists: Trends, Therapeutics and Manufacturing
Overview
This one‑day programme would provide an evidence‑based overview of GLP‑1 receptor agonists, covering the underlying biology, current and emerging clinical use, and a high‑level view of the end‑to‑end manufacturing route.
Key topics covered
- Describe the physiology of the incretin system and the mechanism of action of GLP 1 RAs
- Compare approved GLP 1 RAs in terms of structure, PK, and clinical indications
- Critically review emerging clinical data and indications
- Explain, at a high level, the biosynthetic and chemical manufacturing route for peptide based GLP 1 therapies
- Identify key quality, regulatory, and supply chain considerations
- Discuss future trends (next generation agonists, oral formulations, etc.)
Who should attend
This course is designed for professionals seeking a structured, high-level understanding of GLP‑1 receptor agonists, from biology through to clinical application and manufacturing considerations. It is particularly suited to individuals who are new to this therapeutic area or who require cross-functional awareness rather than deep technical specialisation.
Relevant roles include:
Scientists and engineers in biopharma (early career or transitioning into peptide/GLP‑1 areas)
Technical, manufacturing, and process development staff seeking broader context on GLP‑1 products
Quality, regulatory, and supply chain professionals supporting peptide-based therapeutics
Clinical, medical affairs, or commercial personnel requiring a scientific overview of GLP‑1 RAs
Anyone with an interest in understanding the science, therapeutic landscape, and production of GLP‑1 receptor agonists
No prior in-depth knowledge of GLP‑1 therapies is required, although a basic background in life sciences or biopharmaceuticals would be beneficial.
Register
Course Format
Full course onsite at NIBRT
- 1 full day onsite training at NIBRT facility
Dates & Price
Dates:
- Course 1 19/10/2026€995.00
10 Places Remaining
